The China-focused SK Biopharmaceuticals spinoff raised cash in a series A round led by 6 Dimensions Capital that included Ruentex Group.

Ignis Therapeutics, a China-based central nervous system (CNS) therapy developer established by drug producer SK Biopharmaceuticals, secured $180m in series A funding yesterday, DealStreetAsia reported, citing a company statement.

The round was led by 6 Dimensions Capital, the healthcare investment firm formed by pharmaceutical firm WuXi AppTec’s WuXi Healthcare Ventures vehicle and venture capital firm Frontline BioVentures.

Industrial conglomerate Ruentex Group also participated in the round, as did KB Investment, WTT Investment, Mubadala Investment Company, HBM Healthcare Investments and Goldman…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Robert Lavine

Robert Lavine is special features editor for Global Venturing.
Email LinkedIn